The metabolic medicine sector has spent the better part of a decade consolidating around a single biological mechanism: the GLP-1 receptor. Drugs that mimic glucagon-like peptide-1 — most notably Eli Lilly's Zepbound and Novo Nordisk's Wegovy — have generated enormous commercial and clinical momentum by suppressing appetite and improving glycemic control. The category has reshaped how physicians treat obesity and has turned incretin-based therapies into one of the fastest-growing pharmaceutical segments in history.
Now, a peer-reviewed draft published in Molecular Metabolism proposes a provocative alternative. Richard DiMarchi and Matthias Tschöp, two researchers whose earlier work helped lay the scientific groundwork for the current generation of GLP-1 drugs, describe an experimental molecule that bypasses GLP-1 entirely. Instead, it activates receptors for two other gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and glucagon. In studies involving rodents and monkeys, the dual-action compound achieved weight loss comparable to existing blockbuster treatments — without relying on the mechanism that defines them.
The tolerability problem
The rationale for sidestepping GLP-1 is rooted in a well-documented clinical limitation. GLP-1 receptor agonists are effective, but they carry a consistent burden of gastrointestinal side effects. Nausea, vomiting, and related discomfort are among the most frequently reported adverse events in trials of semaglutide and tirzepatide, and they remain a leading reason patients discontinue treatment. For a drug class increasingly prescribed for chronic, long-term use, tolerability is not a secondary concern — it is a structural constraint on adoption.
DiMarchi and Tschöp's hypothesis reframes the pharmacological equation. Rather than treating GLP-1 activation as the indispensable driver of weight loss and layering other hormonal signals on top, their molecule asks whether GIP and glucagon alone — dosed at sufficient levels — can produce equivalent metabolic effects through a different physiological pathway. If the gastrointestinal side-effect profile is indeed tied primarily to GLP-1 receptor engagement, removing that element while preserving efficacy would represent a meaningful advance in drug design.
The concept is not entirely without precedent. Tirzepatide, the active ingredient in Zepbound, already acts on both GLP-1 and GIP receptors, and its clinical profile has prompted debate about how much of its efficacy derives from GIP rather than GLP-1 stimulation. The new molecule extends that logic further, replacing GLP-1 with glucagon — a hormone traditionally associated with raising blood sugar but increasingly understood to play a role in energy expenditure and lipid metabolism.
From animal models to industry implications
The research, funded by BlueWater Biosciences, remains at the preclinical stage. The distance between promising animal data and a viable human therapy is considerable, and the history of metabolic drug development offers no shortage of cautionary examples. Compounds that perform well in rodent models frequently fail to replicate those results in human trials, where the complexity of metabolism, behavior, and long-term safety introduces variables that animal studies cannot fully capture.
Still, the provenance of this work matters. DiMarchi and Tschöp are not outsiders challenging an established paradigm from the margins; they are among its architects. Their willingness to question whether GLP-1 is truly the essential ingredient in metabolic pharmacology carries a different weight than a similar claim from a less established group. It also arrives at a moment when the pharmaceutical industry is investing heavily in next-generation obesity drugs — multi-agonists, oral formulations, and combination therapies — all of which assume GLP-1 as a foundational component.
If the GIP-glucagon approach proves viable in humans, it would not necessarily displace existing GLP-1 drugs, which have extensive clinical validation and an expanding base of real-world evidence. But it could open a parallel therapeutic track — one optimized for patients who cannot tolerate GLP-1-driven side effects or who require chronic treatment regimens where even modest improvements in tolerability compound over years of use.
The central tension is clear enough: the metabolic medicine industry has built its most valuable franchise on a single receptor pathway, and two of the scientists most responsible for that foundation are now suggesting the pathway may be optional. Whether the biology cooperates in human trials remains an open question — but it is one the field can no longer afford to ignore.
With reporting from STAT News.
Source · STAT News (Biotech)
